Generation of Single-Chain/IL-2 Fusion Protein for the Treatment of B-Cell Lymphoma

Generation of Single-Chain/IL-2 Fusion Protein for the Treatment of B-Cell Lymphoma

碩士 === 國立臺灣大學 === 醫事技術學系 === 84 ===

Bibliographic Details
Main Authors:	Sher,Yuh-Pyng, 佘玉萍
Other Authors:	Tao,Mi-Hua
Format:	Others
Language:	zh-TW
Published:	1996
Online Access:	http://ndltd.ncl.edu.tw/handle/15211285337770527642

Similar Items

Characterization of Metastasis Associated Genes and Development of Clinical Prognosis Assay for Lung Cancer
by: Yuh-Pyng Sher, et al.
Published: (2006)

Treatment of B-cell Lymphoma with Chimeric Antibody-Cytokine Fusion Proteins
by: Liu Shih-Jen, et al.
Published: (1998)

Generation of single chain Fv protein A fusion molecules for melanoma therapy
by: Sharma, Vandana
Published: (2006)

Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors
by: Aurora Holgado, et al.
Published: (2020-07-01)

An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
by: Tobias Jahn, et al.
Published: (2012-01-01)

Hints From the Images
by: Yuh-pyng Yu, et al.
Published: (2004)

Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein
by: Ye Qing, et al.
Published: (2012-11-01)

Inhibition of Breast Cancer Metastasis and Angiogenesis by Antiosteopontin Single-Chain Fv-Fc Fusion Protein
by: Ling Peng, et al.
Published: (2009-05-01)

B-Cell lymphoma at the site of pacemaker generator
by: Andreas Keyser, MD, et al.
Published: (2020-08-01)

An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
by: Dongmei Fan, et al.
Published: (2019-09-01)

Production and characterization of a single-chain Fv antibody–alkaline phosphatase fusion protein specific for ampicillin
by: Kuo He, et al.
Published: (2019-01-01)

Plant-derived Murine IL-12 and Ricin B-Murine IL-12 Fusions
by: Liu, Jianyun
Published: (2014)

Characterisation of two anti-tumour single-chain Fv-interleukin-2 fusion proteins and investigation of their immunotherapeutic potential
by: Boleti, Ekaterini
Published: (2002)

Clinical significance of sIL-2R levels in B-cell lymphomas.
by: Noriaki Yoshida, et al.
Published: (2013-01-01)

Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma
by: E A Baryakh, et al.
Published: (2015-08-01)

Diffuse large B-cell lymphoma: a single disease?
by: Paulo Castañeda-Ruiz, et al.
Published: (2017-10-01)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
by: Chao Xue, et al.
Published: (2020-09-01)

Operating Management Study of Nursing Care Facility-An Example of Facility Service Quality Aspect in Central Taiwan
by: Li Yuh Pyng, et al.
Published: (2006)

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
by: Laurent Julien, et al.
Published: (2013-01-01)

Structural and Functional Studies of Cytokine IL-3 and GM-CSF Fusion Proteins
by: 胡志煌
Published: (2002)

Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein
by: Marjan Pourhadi, et al.
Published: (2019-01-01)

Bendamustine in the treatment of B-cell non-Hodgkin lymphoma
by: L G Babicheva, et al.
Published: (2018-12-01)

Light Chain Crystal Podocytopathy in a Patient With Systemic Indolent B-Cell Lymphoma
by: Fareed Kamar, et al.
Published: (2020-03-01)

Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma
by: Osamu Noyori, et al.
Published: (2019-01-01)

Impact of SNPs/Haplotypes of IL10 and IFNG on the Development of Diffuse Large B-Cell Lymphoma
by: Amanda Vansan Marangon, et al.
Published: (2019-01-01)

Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
by: Frédérique Larousserie, et al.
Published: (2019-06-01)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021-02-01)

Bcl-2 protein in diffuse large B-cell lymphoma
by: Viroj Wiwanitkit
Published: (2011-01-01)

Multimeric fusion single‐chain variable fragments as potential novel high‐capacity ligands
by: Laila I. Sakhnini, et al.
Published: (2020-04-01)

A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.
by: Yang Buyue, et al.
Published: (2014-01-01)

IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch
by: Maria Abreu, et al.
Published: (2021-01-01)

The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo
by: Mi-Ae Lyu, et al.
Published: (2010-05-01)

Diffuse large B cell lymphoma coexistence with systemic mastocytosis
by: Sheng-Hsuan Chien, et al.
Published: (2016-06-01)

B-cell lymphoma, unclassifiable, intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma
by: E A Baryakh, et al.
Published: (2015-04-01)

IL2-based fusion proteins as new bi-functional biopharmaceuticals for the therapy of cancer
by: Penafuerte Diaz, Claudia
Published: (2011)

Next generation monoclonal antibodies and their mechanisms of action against B-cell lymphomas
by: Peri, Delila
Published: (2012)

The importance of next generation sequence in patients with diffuse large B cell lymphoma
by: A. Bolaman, et al.
Published: (2020-10-01)

Generation and affinities with antigen of single chain variable fragment antibody against Odontoglossum ringspot virus from phage display library
by: Chiou-Ping You, et al.
Published: (2005)

Current trends in pediatric aggressive B-cell lymphomas treatment
by: Yu. S. Korkina, et al.
Published: (2021-06-01)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas
by: Bhawana George, et al.
Published: (2020-05-01)